Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Wyles

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Open Forum Infectious Diseases|November 16, 2018
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical TrialsJason Grebely, Massimo Puoti, Heiner Wedemeyer, et al.
The Journal of Infectious Diseases|March 24, 2020
Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S SubstudyAshwin Balagopal, Laura M Smeaton, Jeffrey Quinn, et al.
Hepatology (Baltimore, Md.)|February 7, 2014
All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infectionDavid L Wyles, Maribel Rodriguez-Torres, Eric Lawitz, et al.
The Journal of Antimicrobial Chemotherapy|August 9, 2020
Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvirKristina M Brooks, Jose R Castillo-Mancilla, Mary Morrow, et al.
Annals of Internal Medicine|November 10, 2015
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized TrialGregory T Everson, William J Towner, Mitchell N Davis, et al.
Trials|January 28, 2023
The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for Hepatitis C (Hep C) Linkage-to-Care Trial: rationale and design of an emergency department-based randomized clinical trial of linkage-to-care strategies for hepatitis CSarah E Rowan, Jason Haukoos, Kevin F Kamis, et al.
JAMA|July 9, 2025
Hepatitis C Screening in Emergency Departments: The DETECT Hep C Randomized Clinical TrialJason Haukoos, Richard E Rothman, James W Galbraith, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 1, 2014
Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trialsEvguenia S Svarovskaia, Hadas Dvory-Sobol, Neil Parkin, et al.
Trials|April 26, 2022
The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for Hepatitis C (Hep C) Screening Trial: rationale and design of a multi-center pragmatic randomized clinical trial of hepatitis C screening in emergency departmentsJason S Haukoos, Sarah E Rowan, James W Galbraith, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 30, 2025
Short Course Therapy With Glecaprevir/Pibrentasvir for Early Hepatitis C Virus Infection: PURGE-CArthur Y Kim, Minhee Kang, Triin Umbleja, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Open Forum Infectious Diseases|November 16, 2018
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical TrialsJason Grebely, Massimo Puoti, Heiner Wedemeyer, et al.
The Journal of Infectious Diseases|March 24, 2020
Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S SubstudyAshwin Balagopal, Laura M Smeaton, Jeffrey Quinn, et al.
Hepatology (Baltimore, Md.)|February 7, 2014
All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infectionDavid L Wyles, Maribel Rodriguez-Torres, Eric Lawitz, et al.
The Journal of Antimicrobial Chemotherapy|August 9, 2020
Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvirKristina M Brooks, Jose R Castillo-Mancilla, Mary Morrow, et al.
Annals of Internal Medicine|November 10, 2015
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized TrialGregory T Everson, William J Towner, Mitchell N Davis, et al.
Trials|January 28, 2023
The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for Hepatitis C (Hep C) Linkage-to-Care Trial: rationale and design of an emergency department-based randomized clinical trial of linkage-to-care strategies for hepatitis CSarah E Rowan, Jason Haukoos, Kevin F Kamis, et al.
JAMA|July 9, 2025
Hepatitis C Screening in Emergency Departments: The DETECT Hep C Randomized Clinical TrialJason Haukoos, Richard E Rothman, James W Galbraith, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 1, 2014
Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trialsEvguenia S Svarovskaia, Hadas Dvory-Sobol, Neil Parkin, et al.
Trials|April 26, 2022
The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for Hepatitis C (Hep C) Screening Trial: rationale and design of a multi-center pragmatic randomized clinical trial of hepatitis C screening in emergency departmentsJason S Haukoos, Sarah E Rowan, James W Galbraith, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 30, 2025
Short Course Therapy With Glecaprevir/Pibrentasvir for Early Hepatitis C Virus Infection: PURGE-CArthur Y Kim, Minhee Kang, Triin Umbleja, et al.
Pageof 8